Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H12ClNO4 |
| Molecular Weight | 245.66 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)OCC(O)COC1=CC=C(Cl)C=C1
InChI
InChIKey=SKPLBLUECSEIFO-UHFFFAOYSA-N
InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)
DescriptionSources: doi:10.1001/jama.1966.03100220075024Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Sources: doi:10.1001/jama.1966.03100220075024
Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Chlorphenesin carbamate (Maolate, Musil) is a centrally acting muscle relaxant used to treat muscle pain and spasms. Сhlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. It also has antifungal and some antibacterial properties. The major adverse effects are drowsiness and dizziness.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: nerve impulses Sources: https://www.drugs.com/mtm/maolate.html |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: DOI:10.1001/jama.1966.03100220075024 |
Primary | MAOLATE Approved UseUnknown Launch Date1965 |
||
| Curative | MAOLATE Approved UseUnknown Launch Date1965 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Relative bioavailability of generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in healthy Korean volunteers: a single-dose, randomized-sequence, open-label, two-period crossover trial. | 2009-11 |
|
| Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. | 2003-01-03 |
Patents
Sample Use Guides
for adults is 1.6 to 2.4 gm given in divided doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6967526
chlorphenesin carbamate (CPC) has an apparent depressing action on the spinal neuron. CPC caused marked hyperpolarizations and depressed spontaneous activities in both of the primary afferent terminals (PAT) and motoneurons (MN).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.434
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2724
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
C65322
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
m3455
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | Merck Index | ||
|
886-74-8
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
Chlorphenesin carbamate
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
20880
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | RxNorm | ||
|
C015071
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
DTXSID5022803
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
82943
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
57U5YI11WP
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
3643
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
SUB01245MIG
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
212-954-7
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
57U5YI11WP
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
614
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
100000084718
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
3031
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
CHEMBL607710
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY | |||
|
DB14656
Created by
admin on Mon Mar 31 18:20:04 GMT 2025 , Edited by admin on Mon Mar 31 18:20:04 GMT 2025
|
PRIMARY |
ACTIVE MOIETY